CD4+ TIL 靶向 MHC-II 挽救抗 PD-1 失败。
CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.
机构信息
Stanford Cancer Institute, Palo Alto, California.
Department of Medicine, Stanford University, Stanford, California.
出版信息
Clin Cancer Res. 2023 Oct 2;29(19):3829-3831. doi: 10.1158/1078-0432.CCR-23-1333.
Abstract
In this CCR Translations, we discuss the potential for tumor-infiltrating lymphocyte therapy to overcome immune checkpoint inhibitor resistance through CD4+-mediated and MHC-II-dependent killing. Validating these results from human tumors has potential to improve the clinical application of adoptive cellular transfer in advanced cancers. See related article by Draghi et al., p. 3937.
摘要
在这篇 CCR 翻译中，我们讨论了肿瘤浸润淋巴细胞疗法通过 CD4+介导和 MHC-II 依赖性杀伤来克服免疫检查点抑制剂耐药性的潜力。验证这些来自人类肿瘤的结果有可能改善过继细胞转移在晚期癌症中的临床应用。请参阅 Draghi 等人的相关文章，第 3937 页。
相似文献
1
CD4+ TIL to the Rescue of Anti-PD-1 Failure by Targeting MHC-II.CD4+ TIL 靶向 MHC-II 挽救抗 PD-1 失败。
Clin Cancer Res. 2023 Oct 2;29(19):3829-3831. doi: 10.1158/1078-0432.CCR-23-1333.
2
Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes.肿瘤特异性 CD4+ 黑色素瘤肿瘤浸润淋巴细胞。
J Immunother. 2012 Jun;35(5):400-8. doi: 10.1097/CJI.0b013e31825898c5.
3
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.解除 CD4+ TIL 介导的肿瘤杀伤与黑色素瘤中 JAK 信号的关联。
Clin Cancer Res. 2023 Oct 2;29(19):3937-3947. doi: 10.1158/1078-0432.CCR-22-3853.
4
Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.通过逆转录病毒介导的单一T细胞受体转移同时产生CD8 +和CD4 +黑色素瘤反应性T细胞。
Cancer Res. 2005 Feb 15;65(4):1570-6. doi: 10.1158/0008-5472.CAN-04-2076.
5
Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.乳腺癌中肿瘤浸润淋巴细胞介导的肿瘤特异性细胞溶解作用。
Cancer. 1994 Aug 15;74(4):1275-82. doi: 10.1002/1097-0142(19940815)74:4<1275::aid-cncr2820740416>3.0.co;2-q.
6
Tumor-infiltrating lymphocytes in melanoma.黑色素瘤中的肿瘤浸润淋巴细胞。
Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5.
7
Neoantigen-specific CD4 tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.过继细胞治疗转移性黑色素瘤患者产品中鉴定到的新抗原特异性 CD4 肿瘤浸润淋巴细胞是有效的效应细胞。
J Immunother Cancer. 2023 Oct;11(10). doi: 10.1136/jitc-2023-007288.
8
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.嵌合抗原受体 T 细胞（CAR-T）治疗血液系统恶性肿瘤的中国专家共识（2023 年版）
Clin Cancer Res. 2011 Apr 1;17(7):1664-73. doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15.
9
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.针对免疫检查点分子的抗体恢复了肝癌浸润 T 细胞的功能。
Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.
10
MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.人CD4 +肿瘤浸润淋巴细胞对黑色素瘤抗原的MHC I类限制性识别。
Cancer Res. 1999 Dec 15;59(24):6230-8.
引用本文的文献
1
TIL Therapy in Lung Cancer: Current Progress and Perspectives.肺癌中的肿瘤浸润淋巴细胞疗法：当前进展与展望
Adv Sci (Weinh). 2024 Dec;11(46):e2409356. doi: 10.1002/advs.202409356. Epub 2024 Oct 18.
本文引用的文献
1
CD4 T cell-induced inflammatory cell death controls immune-evasive tumours.CD4 T 细胞诱导的炎症细胞死亡控制免疫逃避肿瘤。
Nature. 2023 Jun;618(7967):1033-1040. doi: 10.1038/s41586-023-06199-x. Epub 2023 Jun 14.
2
Uncoupling CD4+ TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma.解除 CD4+ TIL 介导的肿瘤杀伤与黑色素瘤中 JAK 信号的关联。
Clin Cancer Res. 2023 Oct 2;29(19):3937-3947. doi: 10.1158/1078-0432.CCR-22-3853.
3
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.在免疫检查点抑制剂和靶向治疗进展后，晚期黑色素瘤患者单次自体肿瘤浸润淋巴细胞（TIL）细胞治疗 lifileucel 的疗效和安全性：C-144-01 研究连续队列的汇总分析。
J Immunother Cancer. 2022 Dec;10(12). doi: 10.1136/jitc-2022-005755.
4
Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.肿瘤浸润淋巴细胞治疗黑色素瘤：从现实到未来。
Clin Cancer Res. 2023 May 15;29(10):1835-1854. doi: 10.1158/1078-0432.CCR-22-1922.
5
Landscape of helper and regulatory antitumour CD4 T cells in melanoma.黑色素瘤中辅助和调节抗肿瘤 CD4 T 细胞的景观。
Nature. 2022 May;605(7910):532-538. doi: 10.1038/s41586-022-04682-5. Epub 2022 May 4.
6
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers.转移性人类癌症中抗肿瘤新生抗原反应性 T 细胞的分子特征。
Science. 2022 Feb 25;375(6583):877-884. doi: 10.1126/science.abl5447. Epub 2022 Feb 3.
7
Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes.乳腺癌具有免疫原性：免疫分析和使用突变反应性自体淋巴细胞的 II 期临床试验。
J Clin Oncol. 2022 Jun 1;40(16):1741-1754. doi: 10.1200/JCO.21.02170. Epub 2022 Feb 1.
8
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.利弗利塞（一种肿瘤浸润淋巴细胞疗法）治疗转移性黑色素瘤。
J Clin Oncol. 2021 Aug 20;39(24):2656-2666. doi: 10.1200/JCO.21.00612. Epub 2021 May 12.
9
The Next Decade of Immune Checkpoint Therapy.免疫检查点治疗的下一个十年。
Cancer Discov. 2021 Apr;11(4):838-857. doi: 10.1158/2159-8290.CD-20-1680.
10
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8 T Cells in Non-Melanoma Cancers Compared to Melanoma.对不同人类肿瘤类型中肿瘤浸润淋巴细胞的定性分析显示，与黑色素瘤相比，非黑色素瘤癌症中旁观者CD8 T细胞的比例更高。
Cancers (Basel). 2020 Nov 12;12(11):3344. doi: 10.3390/cancers12113344.
Zotero 插件